Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions

ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions

US Patent 9212227 · Granted Dec 15, 2015

Estimated economic value: $77,496,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Biomarkers for graft-versus-host disease2025
Antigen binding regions against fibronectin type III domains and methods of usin2025
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof2025
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof2025
Anti-PHF-tau antibodies and uses thereof2025
Anti-PHF-tau antibodies and uses thereof2025
Biomarkers for graft-versus-host disease2025
Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses2024
Anti-IL-23 antibodies, compositions, methods and uses2024
Biomarkers for graft-versus-host disease2024
Proteins comprising CD3 antigen binding domains and uses thereof2024
Proteins comprising kallikrein related peptidase 2 antigen binding domains and t2024